Cellular & Molecular Immunology is a prestigious peer-reviewed journal published by the CHIN SOCIETY IMMUNOLOGY. As a leading journal in the fields of immunology and infectious diseases, it proudly holds a Q1 designation across multiple categories, including Immunology, Allergy, and Medicine (Miscellaneous), reflecting its commitment to excellence and impactful research. With an ISSN of 1672-7681 and an E-ISSN of 2042-0226, the journal has been essential reading since its inception in 2004, continuously gathering insights from cutting-edge studies. It ranks impressively within Scopus, with positions in the 7th, 8th, and 9th percentile in relevant categories, establishing it as a cornerstone for researchers, clinicians, and students alike. The journal offers an extensive range of original research articles, reviews, and clinical studies, ensuring that readers stay at the forefront of immunological discovery. Whether you are interested in basic immunology, infectious diseases, or evolving therapies, Cellular & Molecular Immunology serves as an invaluable resource for advancing your knowledge and engagement in this dynamic field.

International Immunopharmacology, published by Elsevier, stands as a prominent journal within the disciplines of immunology and pharmacology. With an ISSN of 1567-5769 and an E-ISSN of 1878-1705, this esteemed journal is based in the Netherlands and features a robust commitment to disseminating high-quality research from its inception in 2001 through 2024. The journal has achieved impressive rankings, securing a Q1 category in Pharmacology and Q2 in both Immunology and Immunology and Allergy as of 2023. With its strategic focus on bridging the gap between immunology and pharmacological applications, International Immunopharmacology attracts a diverse readership, including researchers, healthcare professionals, and students interested in the latest advancements in therapeutic agents and immune system modulation. Furthermore, it offers an open access option, enhancing the accessibility and reach of its invaluable content. As a pivotal resource in the field, this journal not only facilitates the exchange of innovative ideas but also fosters a deeper understanding of the complexities of immunopharmacology in today’s research landscape.

Scandinavian Journal of Immunology is a prestigious peer-reviewed journal published by Wiley, focused on the evolving field of immunology and its interdisciplinary ties with medicine. Since its inception in 1972, this journal has cultivated a rich repository of knowledge, showcasing innovative research and reviews that contribute to the understanding of immune system functions, disorders, and therapeutic interventions. With an impressive impact factor reflecting a Q2 ranking in Immunology and a top-tier Q1 status in miscellaneous Medicine categories for 2023, it is recognized for its high-quality scholarly output, positioning it among the leading journals in the field. Additionally, its Scopus ranking of #84 out of 236 in Immunology underscores its significance and relevance to both emerging and established researchers. Although it does not currently offer open access options, the journal’s expansive reach and rigorous publication standards make it an essential platform for disseminating impactful research to the global scientific community. The journal invites submissions that explore the complexities of the immune system, aiming to bridge clinical and basic science for a comprehensive understanding of immunological phenomena.

The Egyptian Rheumatologist is a peer-reviewed Open Access journal dedicated to advancing the field of rheumatology. Published by Elsevier since 2011, the journal aims to disseminate high-quality research, clinical innovations, and reviews that cover a wide range of topics related to autoimmune diseases, arthritis, and musculoskeletal disorders. With an ISSN of 1110-1164 and an E-ISSN of 2090-2433, it has achieved a respectable rank of #50 out of 73 in the medicine/rheumatology category according to Scopus, positioning it in the 32nd percentile among its peers. Operating from its base in Amsterdam, Netherlands, the journal provides an accessible platform for researchers, professionals, and students, encouraging a collaborative exchange of cutting-edge knowledge that is essential for the ongoing developments in rheumatologic care and research. The Open Access model ensures that critical findings and advancements are available to a global audience, fostering further research and education within this vital field.

ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

IMUNOLOGY AND CELL BIOLOGY, published by Wiley, serves as a prominent platform for disseminating cutting-edge research in the fields of immunology and cell biology. With an ISSN of 0818-9641 and an E-ISSN of 1440-1711, this journal has established itself since its inception in 1987, demonstrating a commitment to advancing knowledge in its disciplines through high-quality articles. Renowned for its rigorous peer-review process, it holds a Q2 quartile ranking in both immunology and cell biology categories as of 2023, showing its competitive stature in these fields. IMUNOLOGY AND CELL BIOLOGY is indexed among the elite journals worldwide, with impressive Scopus rankings, including a rank of #75/233 in Immunology and Allergy. The journal’s comprehensive scope ensures that it caters to an audience of researchers, professionals, and students who are dedicated to exploring the intricate mechanisms of immune responses and cellular interactions. Although it does not operate under an open access model, its subscription-based content remains invaluable for those seeking to broaden their understanding of immunology and cell biology. By providing a forum for significant scientific dialogue, IMUNOLOGY AND CELL BIOLOGY continues to shape the future of research in these vital areas.

AIMS Allergy and Immunology is a prestigious open access journal dedicated to advancing knowledge in the fields of allergy and immunology. Published by the American Institute of Mathematical Sciences (AIMS), this journal provides a vibrant platform for researchers, practitioners, and scholars to share groundbreaking findings and insights. Recognized for its commitment to disseminating high-quality research since its inception in 2017, AIMS Allergy and Immunology contributes significantly to the understanding of complex immunological mechanisms and allergic responses, thus playing a pivotal role in enhancing clinical practices and therapeutic strategies. With its ISSN 2575-615X, the journal aims to facilitate a robust exchange of ideas and promote collaboration within the scientific community. Researchers and practitioners are encouraged to access the latest studies and reviews, which are all freely available online, ensuring that vital information reaches a global audience without barriers. Together, we can tackle the challenges posed by allergies and immune disorders through rigorous scientific inquiry and innovation.

HUMAN IMMUNOLOGY, published by Elsevier Science Inc, serves as a critical platform for disseminating research in the fields of immunology and allergy, as well as various aspects of miscellaneous medicine since its inception in 1980. With an ISSN of 0198-8859 and E-ISSN 1879-1166, this journal is pivotal for researchers and practitioners looking to advance their understanding of human immune responses and related conditions. The journal currently holds a respectable position within its field, as highlighted by its 2023 Scopus ranks—#114/233 in Immunology and Allergy and #132/236 in Immunology and Microbiology. Moreover, it maintains a Q2 quartile ranking in both Immunology and Allergy and miscellaneous Medicine, underscoring its influence and reach within the scientific community. Although it does not currently offer Open Access options, HUMAN IMMUNOLOGY remains dedicated to providing valuable insights and fostering academic discourse within its discipline, characterized by a rigorous peer-review process and a focus on innovative research trajectories.

Journal of Inflammation Research, published by Dove Medical Press Ltd, is a premier open-access journal dedicated to advancing the field of immunology and allergy, with a particular focus on the biological mechanisms underlying inflammation. Since its inception in 2008, this journal has provided a vital platform for researchers to share their findings and foster collaboration within the global scientific community. With an impressive 2023 impact factor placing it in the Q2 category for both Immunology and Immunology and Allergy, the journal has consistently maintained its relevance and high academic standards, ranking #100 in Medicine (Immunology and Allergy) and #118 in Immunology (Immunology and Microbiology) according to Scopus metrics. The E-ISSN 1178-7031 allows for easy access to a plethora of pioneering research articles, reviews, and clinical studies that address contemporary issues in inflammation and immunity. As a leading resource for researchers, professionals, and students alike, Journal of Inflammation Research is committed to facilitating the dissemination of groundbreaking discoveries that contribute to improved therapeutic strategies and health outcomes.

Central European Journal of Immunology is a premier publication dedicated to advancing the field of immunology and allergy research. Established in 1996 and published by TERMEDIA PUBLISHING HOUSE LTD, this open access journal has consistently provided a platform for innovative research and comprehensive reviews since its transition to open access in 2002. With an ISSN of 1426-3912 and E-ISSN of 1644-4124, it embraces a global readership while being rooted in Poland. The journal, with a notable Q3 ranking in both the categories of immunology and allergy in 2023, positions itself within the competitive landscape of scientific discourse, as reflected in its Scopus rankings. Designed for researchers, professionals, and students, the Central European Journal of Immunology not only disseminates significant findings but also fosters collaboration and innovation in the immunological sciences, making it a vital resource for those seeking to stay current in this rapidly evolving field.